Cas:54039-38-2 Bis(pentamethylcyclopentadienyl)zirconium dichloride manufacturer & supplier

Chemical Name:Bis(pentamethylcyclopentadienyl)zirconium dichloride

CAS.NO:54039-38-2

Synonyms:Bis(pentamethylcyclopentadienyl)zirconium dichloride;Bis(2,3,4,5,5-pentamethyl-1,3-cyclopentadien-1-yl)zirconium(2+) dichloride;Zirconium(2+), bis(2,3,4,5,5-pentamethyl-1,3-cyclopentadien-1-yl)-, chloride (1:2);DecaMethylzirconocene Dichloride;Bis(2,3,4,5,5-pentamethylcyclopenta-1,3-dien-1-yl)zirconium(2+) dichloride;MFCD00058849

Molecular Formula:C₂₀H₃₀Cl₂Zr

Molecular Weight:432.582

HS Code:

Physical and Chemical Properties:

Melting point:300ºC

Boiling point:170.2ºC at 760 mmHg

Density:N/A

Index of Refraction:

PSA:

Exact Mass:430.077148

LogP:7.32300

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:UN 3261

Packing Group:II

Contact us for information like Bis(pentamethylcyclopentadienyl)zirconium dichloride chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00058849 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Zirconium(2+), bis(2,3,4,5,5-pentamethyl-1,3-cyclopentadien-1-yl)-, chloride (1:2) Use and application,Bis(2,3,4,5,5-pentamethylcyclopenta-1,3-dien-1-yl)zirconium(2+) dichloride technical grade,usp/ep/jp grade.

Related News: Rigosertib, Onconova��s lead candidate, is a proprietary Phase 3 small molecule. Bis(pentamethylcyclopentadienyl)zirconium dichloride manufacturer The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. Bis(pentamethylcyclopentadienyl)zirconium dichloride supplier Russia, which had temporarily stopped issuing work visas to Chinese citizens, is also halting visa-free entry for Chinese tour groups, the government said. Moscow has also stopped issuing electronic tourist visas to individual Chinese travelers. Bis(pentamethylcyclopentadienyl)zirconium dichloride vendor The clinical trial International Study of Phase 3 IV RigosErtib, or INSPIRE, was finalized following guidance received from the U.S. Food and Drug Administration and European Medicines Agency. Bis(pentamethylcyclopentadienyl)zirconium dichloride factory The GLOW trial doesn’t yet have the answer to that question, but Tendler pointed to encouraging early evidence from the regimen’s phase 2 trial, dubbed CAPTIVATE. Among eight patients who progressed after stopping the fixed-duration combo, six responded to subsequent Imbruvica monotherapy, while the other two didn’t have a response report, according to data presented at the recent American Society of Clinical Oncology annual meeting.